CAH Earnings Date: Nov 5, 2026 (Estimated) — Cardinal Health, Inc.
NYSE · Healthcare · Medical Distribution
Updated
When is CAH's next earnings date?
Cardinal Health, Inc. (CAH) is expected to report Q1 2027 earnings on Thursday, November 5, 2026 at 6:00 AM ET (before market open); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of $2.94 on revenue of $66.67B.
How did CAH do in its last earnings report?
In its most recent report on Aug 11, 2026 (Q4 2026), Cardinal Health, Inc. posted EPS of $2.91 versus the $2.42 estimate, a beat of 20.3%. Revenue was $63.67B against a $65.15B estimate. The stock's 1-day post-earnings move was +1.3%.
How much does CAH stock move after earnings?
CAH beat EPS estimates in 8 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 6.1% (up or down) in the day after earnings.
About Cardinal Health, Inc.
Cardinal Health, Inc. operates as a global, integrated provider of healthcare services and products, with its reach spanning the United States, Canada, Europe, Asia, and other international markets. The company delivers bespoke support to a diverse clientele, including hospitals, healthcare networks, pharmacies, outpatient surgical centers, clinical labs, physician practices, and individuals receiving care at home. It is structured into two core divisions: Pharmaceutical and Medical. The Pharmaceutical division oversees the distribution of a wide array of products, encompassing branded, generic, and specialty pharmaceuticals, along with over-the-counter health and consumer goods. This segment additionally offers specialized services to pharmaceutical manufacturers and healthcare providers, particularly for specialty pharmaceutical products. Its operations extend to managing nuclear pharmacies and facilities that produce radiopharmaceuticals. It also performs repackaging of generic drugs and OTC items. Further offerings include medication therapy management and patient outcomes services for hospitals, other healthcare providers, and payers, in addition to providing pharmacy management solutions to hospitals. The Medical division focuses on producing, sourcing, and supplying Cardinal Health-branded medical, surgical, and laboratory products and devices. This extensive product range encompasses items such as examination and surgical gloves, needles, syringes, sharps disposal units, compression products, incontinence aids, nutritional delivery systems, wound care supplies, single-use drapes, gowns, and apparel, fluid suction and collection devices, urological products, operating room essentials, and electrodes. Beyond its proprietary brands, this segment also distributes various national brand medical, surgical, and laboratory products. It offers comprehensive supply chain management for hospitals, ambulatory surgery centers, clinical laboratories, and other healthcare organizations, and manufactures and sells both sterile and non-sterile procedure kits. Established in 1979, the company maintains its headquarters in Dublin, Ohio.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-11 | Q4 2026 | 2.42 | 2.91 | +20.25% | $63.67B | ✅ Beat | +1.30% | -0.64% | +1.19% |
| 2026-04-30 | Q3 2026 | 2.80 | 3.17 | +13.21% | $60.94B | ✅ Beat | -4.90% | -5.59% | -2.97% |
| 2026-02-05 | Q2 2026 | 2.37 | 2.63 | +10.97% | $65.63B | ✅ Beat | +9.83% | +8.41% | +5.29% |
| 2025-10-30 | Q1 2026 | 2.19 | 2.55 | +16.44% | $64.01B | ✅ Beat | +15.42% | +19.65% | +29.06% |
| 2025-08-12 | Q4 2025 | 2.03 | 2.08 | +2.46% | $60.16B | ✅ Beat | -7.21% | -5.03% | -5.31% |
| 2025-05-01 | Q3 2025 | 2.17 | 2.35 | +8.29% | $54.88B | ✅ Beat | +3.00% | +8.63% | +9.30% |
| 2025-01-30 | Q2 2025 | 1.76 | 1.93 | +9.66% | $55.26B | ✅ Beat | +0.39% | -0.25% | +1.34% |
| 2024-11-01 | Q1 2025 | 1.62 | 1.88 | +16.05% | $52.28B | ✅ Beat | +7.01% | +8.94% | +12.86% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q4 FY26 · $127.73B total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| Pharmaceutical Member | 92.4% | $118.05B | +113.2% | $47.99B | $50.85B | $50.43B | $55.37B |
| GMPD | 4.9% | $6.31B | +97.3% | $3.12B | $3.15B | $3.16B | $3.20B |
| Other Operating | 2.6% | $3.36B | +108.9% | $1.19B | $1.28B | $1.30B | $1.61B |
By region
Q4 FY26 · $127.73B total
| Segment | Share | Revenue | YoY | Q1 FY25 | Q2 FY25 | Q3 FY25 | Q4 FY25 |
|---|---|---|---|---|---|---|---|
| UNITED STATES | 99.3% | $126.88B | +112.4% | $51.89B | $54.86B | $54.50B | $59.75B |
| Non-US | 0.7% | $847.0M | +95.2% | $408.0M | $428.0M | $399.0M | $434.0M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.